Orexigen (OREX) is +152% premarket after an FDA advisory panel voted 13-7 to recommend the...

|About: Orexigen Therapeutics, Inc. (OREX)|By:, SA News Editor

Orexigen (OREX) is +152% premarket after an FDA advisory panel voted 13-7 to recommend the approval of diet drug Contrave. The decision came as a surprise, as the FDA has set a very high bar for diet drugs and already rejected several other obesity treatments this year. Rivals gaining on the news: VVUS +12.8%, ARNA +9.9%.